APOBEC3C-mediated NF-κB activation enhances clear cell renal cell carcinoma progression

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Clear cell renal cell carcinoma (ccRCC) is the most common kidney cancer, often treatable with immunotherapy.
• Metastatic ccRCC presents treatment challenges, requiring deeper understanding of its molecular drivers.
• Enhanced immune cell infiltration and specific expression profiles in ccRCC suggest therapeutic potential.

Purpose of the Study:

• To investigate the role of APOBEC-3C (A3C) in ccRCC progression.
• To elucidate the molecular mechanisms by which A3C influences ccRCC tumor growth.
• To identify A3C as a potential therapeutic target for ccRCC.

Main Methods:

• RNA-sequencing analysis of ccRCC tissues and cell lines.
• Cell-based assays to assess A3C function and stress response.
• Investigation of A3C's interaction with NF-κB pathway components.

Main Results:

• APOBEC-3C (A3C) is overexpressed in ccRCC and promotes tumor growth.
• A3C acts as a stress-responsive factor critical for ccRCC cell survival.
• A3C stabilizes mRNAs of NF-κB pathway regulators, enhancing its activity.
• A3C depletion leads to cytoplasmic retention of NF-κB subunits and gene deregulation.

Conclusions:

• APOBEC-3C (A3C) plays a critical role in ccRCC development by enhancing NF-κB signaling.
• A3C is a key driver of ccRCC tumor progression.
• A3C represents a promising novel therapeutic target for ccRCC treatment.